USANA Reports 74% Drop in Net Earnings, 72% Effective Tax Rate, and Goodwill Impairment Amid Core Business Decline
Summary
USANA Health Sciences reported a 74.4% decrease in net earnings and a significant rise in its effective tax rate for 2025, alongside a goodwill impairment and a decline in core active customers.
Key Events
-
Net Earnings Plummet 74.4%
Net earnings attributable to USANA decreased by 74.4% to $10.8 million in 2025, down from $42.03 million in 2024, significantly impacting profitability.
-
Diluted EPS Falls Sharply
Diluted earnings per share dropped to $0.58 in 2025, a substantial decrease from $2.19 in the previous year.
-
Effective Tax Rate Soars to 72.4%
The effective tax rate dramatically increased to 72.4% in 2025, up from 44.9% in 2024, largely due to lower U.S. earnings before taxes and relatively similar foreign taxes.
-
Goodwill Impairment and Cost Realignment Charges
The company recognized a $6.527 million non-cash goodwill impairment charge and a $6.463 million one-time cost realignment charge, primarily for employee severance, reflecting operational difficulties.
Analysis
USANA Health Sciences reported a significant decline in its 2025 financial performance, with net earnings attributable to the company plummeting by 74.4% to $10.8 million and diluted EPS falling to $0.58 from $2.19 in the prior year. This sharp drop was primarily driven by a lower operating margin and a substantial increase in the effective tax rate to 72.4% from 44.9%. The company also recorded a $6.527 million goodwill impairment charge and a $6.463 million cost realignment charge, including employee severance, indicating operational challenges. Furthermore, the core nutritional business experienced a notable 14.8% decrease in active customers, signaling fundamental issues despite the Hiya acquisition contributing $130.0 million in sales.
At the time of this filing, USNA was trading at $17.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $323.9M. The 52-week trading range was $16.72 to $38.32. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.